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To the Editor,
Despite the importance of antimicrobial susceptibility testing
(AST) for clinical management of infection and antimicrobial
resistance (AMR) surveillance, the methodologies and breakpoints
of the two most commonly used systems worldwide, Clinical and
Laboratory Standards Institute (CLSI) and European Committee for
Antimicrobial Susceptibility Testing (EUCAST), are far from
harmonized. Both systems are recommended in the World Health
Organization's Global Antimicrobial Resistance Surveillance System
(GLASS) [1]), but how discrepancies between the two systems will
be addressed is unclear.
Mahidol-Oxford Tropical Health Network (MORU) laboratories
in Thailand, Laos, and Cambodia currently use CLSI disc diffusion
AST guidelines for routine diagnostic and research purposes, but
have recently been considering a switch to EUCAST. As part of a
comprehensive review of the practical implications of this, we
examined the impact of discrepancies in CLSI and EUCAST zone
diameter breakpoints on antimicrobial susceptibility interpretation
of frequently isolated Gram-negative organisms at one of our sites,
the Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos, in
2017. We also performed a literature search to compare our results
to published reports.
The Mahosot Microbiology Laboratory receives clinical samples
from Mahosot Hospital and other hospitals within Vientiane and
several provincial sites, participates in the United Kingdom National
External Quality Assessment (NEQAS) scheme for AST, and is work-
ing towards International Organization for Standardization (ISO)
15189 accreditation. Zone diameter data for ﬁrst-line antimicrobial
agents tested according to CLSI standards against all non-duplicate
(ﬁrst isolate per patient) clinical isolates of Escherichia coli, Klebsi-
ella pneumoniae, and Pseudomonas aeruginosa from1 January 2017 to
31 December 2017 were extracted from the Laboratory Information
Management System and interpreted separately using EUCAST 2018
[2] and CLSI 2018 [3] breakpoints as susceptible, intermediate, or
resistant and category agreement (percentage of isolates with the
same result) determined. These organisms were selected as they
were the commonest Gram-negative isolates in 2017 for which both
organisations provide clinical breakpoints, and recent studies have
reported discrepancies in their susceptibility interpretation [4,5].
Results are summarized in Table 1. A total of 428 E. coli, 208
K. pneumoniae, and 78 P. aeruginosa isolates were included. Cipro-
ﬂoxacin resistance rates would have been markedly higher using
EUCAST breakpoints (59.1% vs. 46.5% in E. coli; 37.5% vs. 13.9% in
K. pneumoniae; 28.2% vs. 10.3% in P. aeruginosa). Resistance to
amoxicillineclavulanic acid among E. coli and K. pneumoniaewould
have also increased (52.3% vs. 19.9% and 35.6% vs. 22.1% respec-
tively), reﬂecting the lower resistance breakpoint and the lack of an
intermediate category for this agent in EUCAST Enterobacteriaceae
guidelines. Meropenem resistance rates in P. aeruginosawould have
remained the same, but nine out of 78 (11.5%) isolates would have
been reinterpreted from susceptible to intermediate. Category
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agreement for all other pathogeneantimicrobial combinations
would have been >95%.
These results demonstrate that adopting EUCAST breakpoints
would have signiﬁcantly altered susceptibility reporting for two
ﬁrst-line agents tested against each of the most frequently isolated
Gram-negative pathogens at Mahosot Microbiology Laboratory in
2017. This artiﬁcial change in susceptibility rates, predominantly
driven by reclassiﬁcation of isolates from susceptible to interme-
diate or resistant, is likely to have inﬂuenced antimicrobial selec-
tion by clinicians. This would also have distorted AMR surveillance
data both locally and nationally given that Mahosot Microbiology
Laboratory is one of the few sites in Laos capable of providing AMR
data. Escherichia coli-ciproﬂoxacin and K. pneumoniae-ciproﬂoxacin
are GLASS priority pathogeneantimicrobial combinations, but
category agreement was only 77.8% and 61.5% respectively between
EUCAST and CLSI. It must be noted that updated CLSI ciproﬂoxacin
breakpoints for Enterobacteriaceae and P. aeruginosa are more
closely aligned with EUCAST, meaning some but not all discrep-
ancies in ciproﬂoxacin susceptibility would have been eliminated
had 2019 breakpoints [6,7] been used for the analysis.
Our results are supported by a literature search (see Fig. S1,
Table S1) which identiﬁed 20 articles whose main objective was
comparing susceptibility interpretation between CLSI and EUCAST.
Nineteen out of 20 articles reported signiﬁcant discrepancies in one
or more pathogeneantimicrobial combination, nearly always due
to a reduction in susceptibility rates and/or increase in resistance
rates when applying more restrictive EUCAST breakpoints. A
notable exception was a study from India [8] that reported higher
meropenem and imipenem susceptibility rates in urinary E. coli
isolates using EUCAST breakpoints, underlining the lack of align-
ment between the two systems even for such important combi-
nations. A trend of reduced susceptibility and/or higher resistance
rates with EUCAST breakpoints was evident in the additional 53
articles where both EUCAST and CLSI breakpoints were used for
susceptibility interpretation, many of which were reports of AMR
surveillance data.
In conclusion, discrepancies in clinical breakpoints between
CLSI and EUCAST signiﬁcantly impact susceptibility interpretation
of clinical isolates, with generally lower susceptibility rates when
EUCAST guidelines are used. This has implications not only for
antibiograms at institutions switching between the two AST sys-
tems, but for broader AMR surveillance initiatives comparing data
within and between countries using different systems or over the
time period during which a change in methodology is
implemented. Globally harmonized clinical breakpoints are ur-
gently needed.
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Table 1
Comparison of susceptibilities of E. coli, K. pneumoniae and P. aeruginosa isolated at Mahosot Microbiology Laboratory in 2017 to ﬁrst-line antibiotics using CLSI and EUCAST
criteria
Organism (no. isolates) Antimicrobial agent CLSI 2018 (%) EUCAST 2018 (%) Category agreement (%)
S I R S I R
E. coli (428) Amoxicillin-clavulanic acid 55.6 24.5 19.9 47.7 e 52.3 64.7
Ampicillin 5.8 2.3 91.8 8.2 e 91.8 97.7
Ciproﬂoxacin 50.5 3 46.5 31.3 9.6 59.1 77.8
Gentamicin 58.4 0 41.6 55.1 2.8 42.1 96.7
Ceftriaxone 41.8 0.2 57.9 40.4 1.4 58.2 98.4
Trimethoprim-sulphamethoxazole 25.9 0.5 73.6 25.9 0.2 73.8 99.8
K. pneumoniae (208) Amoxicillin-clavulanic acid 67.3 10.6 22.1 64.4 e 35.6 85.6
Ciproﬂoxacin 72.6 13.5 13.9 47.6 14.9 37.5 61.5
Gentamicin 76.4 0 23.6 73.6 2.9 23.6 97.1
Ceftriaxone 68.8 0 31.3 64.9 3.8 31.3 98.4
Trimethoprim-sulphamethoxazole 63 2.4 34.6 63.9 0.5 35.6 99.8
P. aeruginosa* (78) Ciproﬂoxacin 85.9 3.8 10.3 71.8 0 28.2 82.1
Gentamicin 76.9 0 23.1 75.6 0 24.4 98.7
Meropenem 94.9 0 5.1 83.3 11.5 5.1 88.5
S, susceptible; I, intermediate; R, resistant.
e, no intermediate category.
* Ceftazidime not included due to discordant CLSI and EUCAST disc contents.
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